We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03781063
Recruitment Status : Active, not recruiting
First Posted : December 19, 2018
Last Update Posted : October 26, 2022
Sponsor:
Collaborator:
Linical Accelovance Group
Information provided by (Responsible Party):
Sermonix Pharmaceuticals Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : February 2023
Estimated Study Completion Date : February 2023